Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium

Annals of Clinical and Translational Neurology

Volumn 1, Issue 5, 2014, Pages 319-328

  Xie, Zhongcong ^a   Swain, Celeste A ^a   Ward, Sarah A P ^a   Zheng, Hui ^a   Dong, Yuanlin ^a   Sunder, Neelakantan ^a   Burke, Dennis W ^a   Escobar, Diana ^a   Zhang, Yiying ^a   Marcantonio, Edward R ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANALGESIA; ANESTHESIA; ARTICLE; CEREBROSPINAL FLUID; CONFUSION ASSESSMENT METHOD; CONTROLLED STUDY; DELIRIUM RATING SCALE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIP REPLACEMENT; HUMAN; KNEE REPLACEMENT; MAJOR CLINICAL STUDY; MALE; MEMORIAL DELIRIUM ASSESSMENT SCALE; MENTAL DISEASE ASSESSMENT; NEUROPATHOLOGY; POSTOPERATIVE BRIEF VISUOSPATIAL MEMORY TEST TOTAL RECALL SCORE; POSTOPERATIVE DELIRIUM; POSTOPERATIVE HOPKINS VERBAL LEARNING TEST RETENTION SCORE; POSTOPERATIVE PAIN; PRIORITY JOURNAL;

EID: 84961943595     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.58     Document Type: Article

References (50)

1. Marcantonio ER, Goldman L, Mangione CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. JAMA 1994;271:134–139.
2. Liu LL, Leung JM. Predicting adverse postoperative outcomes in patients aged 80 years or older. J Am Geriatr Soc 2000;48:405–412.
3. Inouye SK. Delirium in older persons. N Engl J Med 2006;354:1157–1165.
4. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. N Engl J Med 2012;367:30–39.
5. Ansaloni L, Catena F, Chattat R, et al. Risk factors and incidence of postoperative delirium in elderly patients after elective and emergency surgery. Br J Surg 2010;97:273–280.
6. Jankowski CJ, Trenerry MR, Cook DJ, et al. Cognitive and functional predictors and sequelae of postoperative delirium in elderly patients undergoing elective joint arthroplasty. Anesth Analg 2011;112:1186–1193.
7. Vasilevskis EE, Han JH, Hughes CG, Ely EW. Epidemiology and risk factors for delirium across hospital settings. Best Pract Res Clin Anaesthesiol 2012;26:277–287.
8. Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. Br J Anaesth 2009;103(suppl 1):i41–i46.
9. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329–344.
10. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512–519.
11. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456–1465.
12. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927–934.
13. Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50:1464–1470.
14. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094–2103.
15. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213–225.
16. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382–389.
17. Blom ES, Giedraitis V, Zetterberg H, et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 2009;27:458–464.
18. Samgard K, Zetterberg H, Blennow K, et al. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 2010;25:403–410.
19. Wallin AK, Hansson O, Blennow K, et al. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? Int J Geriatr Psychiatry 2009;24:638–647.
20. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403–413.
21. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619–627.
22. Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 2011;32(suppl 1):S4–S9.
23. Solomonov I, Korkotian E, Born B, et al. Zn2+-Abeta40 complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons. J Biol Chem 2012;287:20555–20564.
24. Hatip FF, Hatip-Al-Khatib I, Matsunaga Y, et al. Effects of 8-residue beta sheet breaker peptides on aged Abeta40-induced memory impairment and Abeta40 expression in rat brain and serum following intraamygdaloid injection. Curr Alzheimer Res 2010;7:602–614.
25. Shiwany NA, Xie J, Guo Q. Cortical neurons transgenic for human Abeta40 or Abeta42 have similar vulnerability to apoptosis despite their different amyloidogenic properties. Int J Clin Exp Pathol 2009;2:339–352.
26. Gabelle A, Roche S, Geny C, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 2011;26:553–563.
27. Gao CM, Yam AY, Wang X, et al. Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One 2010;5:e15725.
28. Spies PE, Slats D, Sjogren JM, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 2010;7:470–476.
29. Xie Z, McAuliffe S, Swain CA, et al. Cerebrospinal fluid aβ to tau ratio and postoperative cognitive change. Ann Surg 2013;258:364–369.
30. Marcantonio E, Ta T, Duthie E, Resnick NM. Delirium severity and psychomotor types: their relationship with outcomes after hip fracture repair. J Am Geriatr Soc 2002;50:850–857.
31. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med 1990;113:941–948.
32. Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997;13:128–137.
33. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 1988;23:89–97.
34. Inouye SK, Viscoli CM, Horwitz RI, et al. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics. Ann Intern Med 1993;119:474–481.
35. Bruce AJ, Ritchie CW, Blizard R, et al. The incidence of delirium associated with orthopedic surgery: a meta-analytic review. Int Psychogeriatr 2007;19:197–214.
36. Lynch EP, Lazor MA, Gellis JE, et al. The impact of postoperative pain on the development of postoperative delirium. Anesth Analg 1998;86:781–785.
37. Rade MC, Yadeau JT, Ford C, Reid MC. Postoperative delirium in elderly patients after elective hip or knee arthroplasty performed under regional anesthesia. HSS J 2011;7:151–156.
38. Williams-Russo P, Urquhart BL, Sharrock NE, Charlson ME. Post-operative delirium: predictors and prognosis in elderly orthopedic patients. J Am Geriatr Soc 1992;40:759–767.
39. Marcantonio ER. Postoperative delirium: a 76-year-old woman with delirium following surgery. JAMA 2012;308:73–81.
40. Rudolph JL, Marcantonio ER. Review articles: postoperative delirium: acute change with long-term implications. Anesth Analg 2011;112:1202–1211.
41. Sieber FE, Zakriya KJ, Gottschalk A, et al. Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair. Mayo Clin Proc 2010;85:18–26.
42. Leung JM, Sands LP, Lim E, et al. Does preoperative risk for delirium moderate the effects of postoperative pain and opiate use on postoperative delirium? Am J Geriatr Psychiatry 2013;21:946–956.
43. Witlox J, Kalisvaart KJ, de Jonghe JF, et al. Cerebrospinal fluid beta-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260–1267.
44. Seppala TT, Nerg O, Koivisto AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012;78:1568–1575.
45. Fukumoto H, Rosene DL, Moss MB, et al. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004;164:719–725.
46. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.
47. van Gool WA, van de Beek D, Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 2010;375:773–775.
48. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993;47:169–176.
49. Gaykema RP, Goehler LE, Tilders FJ, et al. Bacterial endotoxin induces fos immunoreactivity in primary afferent neurons of the vagus nerve. Neuroimmunomodulation 1998;5:234–240.
50. Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011;7:386–395.e6.